AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12969696 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E(2) (1 mg) combined with gestodene (25 microg)
Number of subjects: 152
Study 12969696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 10231049 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy
Number of subjects: 62
Study 10231049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 8917263 — intervention group
Group type: EXPERIMENTAL
Intervention: Vein grafts
Number of subjects: 95
Study 8917263 — intervention group
Group type: COMPARATOR
Intervention: Ungrafted coronary arteries
Number of subjects: 95
Study 1986889 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 33
Study 1986889 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 33
Study 6366138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal methotrexate dosage regimen derived from CNS volume considerations (CCG-160 series)
Number of subjects: 3241
Study 6366138 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with cranial irradiation (2400 rads) and intrathecal methotrexate (12 mg/m2 six times during consolidation) (CCG-141)
Number of subjects: 3241
Study 6366138 — intervention group
Group type: COMPARATOR
Intervention: Modification of CCG-141 with intrathecal methotrexate initiated during induction (CCG-141A)
Number of subjects: 3241
Study 6366138 — intervention group
Group type: COMPARATOR
Intervention: Maintenance intrathecal chemotherapy
Number of subjects: 3241
Study 6366138 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment strategy
Number of subjects: 3241
Study 3512188 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of fenoterol by metered-dose inhaler
Number of subjects: 20
Study 3512188 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 micrograms of fenoterol by metered-dose inhaler
Number of subjects: 20
Study 3512188 — intervention group
Group type: COMPARATOR
Intervention: isoproterenol
Number of subjects: 20
Study 3512188 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 29212358 — intervention group
Group type: COMPARATOR
Intervention: Family-based intervention delivered by community health workers over 11 sessions for 4 months.
Number of subjects: 361
Study 29127418 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern search
Number of subjects: 84
Study 29127418 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration
Number of subjects: 84
Study 29127418 — intervention group
Group type: EXPERIMENTAL
Intervention: Recency
Number of subjects: 84
Study 29127418 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pattern search belief
Number of subjects: 84
Study 26545996 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot reflexology applied for 40 min
Number of subjects: 80
Study 26545996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 24294687 — intervention group
Group type: EXPERIMENTAL
Intervention: Debridement (at postoperative weeks 2 and 4)
Number of subjects: 0
Study 24294687 — intervention group
Group type: COMPARATOR
Intervention: No debridement
Number of subjects: 0
Study 21208574 — intervention group
Group type: EXPERIMENTAL
Intervention: eszopiclone cotherapy with SSRI (3 mg/d)
Number of subjects: 347
Study 21208574 — intervention group
Group type: COMPARATOR
Intervention: placebo cotherapy
Number of subjects: 347
Study 18376044 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 16491339 — intervention group
Group type: EXPERIMENTAL
Intervention: Articaine 4% with epinephrine 1:200,000
Number of subjects: 155
Study 16491339 — intervention group
Group type: COMPARATOR
Intervention: Articaine 2% with epinephrine 1:200,000
Number of subjects: 155
Study 12734787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg, TID, over 90 days
Number of subjects: 30
Study 12734787 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10952250 — intervention group
Group type: COMPARATOR
Intervention: 6 million units of IFN once a day
Number of subjects: 22
Study 10952250 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 million units of IFN twice a day
Number of subjects: 22
Study 9291768 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 20
Study 9291768 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 8337057 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training program using the Body Bar
Number of subjects: 30
Study 8337057 — intervention group
Group type: COMPARATOR
Intervention: Walking program (control)
Number of subjects: 30
Study 2952685 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 2% gel
Number of subjects: 102
Study 2952685 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin phosphate 1% solution
Number of subjects: 102
Study 28872368 — intervention group
Group type: EXPERIMENTAL
Intervention: PCMcold (cooled to 15°C)
Number of subjects: 11
Study 27062040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hereditary group H++ (both parents myopic)
Number of subjects: 240
Study 27062040 — intervention group
Group type: EXPERIMENTAL
Intervention: Hereditary group H+– (one myopic parent)
Number of subjects: 240
Study 27062040 — intervention group
Group type: COMPARATOR
Intervention: Hereditary group H– (no myopic parents)
Number of subjects: 240
Study 27062040 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic progression among females with myopic parents
Number of subjects: 240
Study 27062040 — intervention group
Group type: COMPARATOR
Intervention: Myopic progression among females with non-myopic parents
Number of subjects: 240
Study 27062040 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up end among males
Number of subjects: 240
Study 27062040 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up end among females
Number of subjects: 240
Study 24612414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1mg/kg loading dose prior to incision, continuous dose of 1mg/kg/h for 24h)
Number of subjects: 77
Study 24612414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5mL saline loading dose, continuous dose of 90mg ketorolac in 240mL saline)
Number of subjects: 77
Study 24612414 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 77
Study 24612414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 77
Study 23614819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine injection
Number of subjects: 34
Study 23614819 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injection (placebo)
Number of subjects: 34
Study 20958890 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (90 mg)
Number of subjects: 350
Study 20958890 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus retinol (5000 IU)
Number of subjects: 350
Study 20958890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 20958890 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc
Number of subjects: 350
Study 20958890 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc plus retinol
Number of subjects: 350
Study 18191012 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer (GI/GV)
Number of subjects: 10
Study 18191012 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer (GII/GVI)
Number of subjects: 10
Study 18191012 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (GIII/GVII)
Number of subjects: 10
Study 18191012 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam (GIV/GVIII)
Number of subjects: 10
Study 18191012 — intervention group
Group type: COMPARATOR
Intervention: Saliva (control group)
Number of subjects: 10
Study 16892428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa blockade
Number of subjects: 0
Study 16892428 — intervention group
Group type: COMPARATOR
Intervention: Heparin with GP IIb/IIIa inhibition
Number of subjects: 0
Study 16892428 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 16892428 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 0
Study 12562653 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CHOP (cyclophosphamide 600 mg/m² i.v., doxorubicin 30 mg/m² i.v., vincristine 1 mg i.v. on day 1 with prednisolone 20 mg bd for days 1-5) every 21 days
Number of subjects: 155
Study 12562653 — intervention group
Group type: COMPARATOR
Intervention: MCOP (mitozantrone 10 mg/m² i.v. substituted for doxorubicin)
Number of subjects: 155
Study 10868022 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-patient treatment
Number of subjects: 0
Study 10868022 — intervention group
Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 0
Study 10868022 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 0
Study 9339937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC) devices applied for 120 minutes
Number of subjects: 12
Study 8219141 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam/Tramadol
Number of subjects: 40
Study 8219141 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Tramadol
Number of subjects: 40
Study 3895937 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin/Ampicillin
Number of subjects: 825
Study 3895937 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 825
Study 31833413 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography with FFRCT
Number of subjects: 223
Study 31833413 — intervention group
Group type: COMPARATOR
Intervention: FFRCT assessment
Number of subjects: 223
Study 27666149 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide-oxygen mixture (50% N2 O-O2)
Number of subjects: 66
Study 27666149 — intervention group
Group type: COMPARATOR
Intervention: Medical air (22% O2 - 78% N2)
Number of subjects: 66
Study 26001996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% plain
Number of subjects: 3
Study 26001996 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:1 mixture of lidocaine 1% plain and bupivacaine 0.25%
Number of subjects: 3
Study 26001996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential injections of lidocaine 1% plain followed by bupivacaine 0.25% 1h later
Number of subjects: 3
Study 23349357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightning days
Number of subjects: 90
Study 23349357 — intervention group
Group type: COMPARATOR
Intervention: Non-lightning days
Number of subjects: 90
Study 23349357 — intervention group
Group type: EXPERIMENTAL
Intervention: Average current of lightning strikes
Number of subjects: 90
Study 21573144 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryptococcus neoformans variety grubii isolates from Thailand
Number of subjects: 183
Study 21573144 — intervention group
Group type: COMPARATOR
Intervention: Comparison with global MLST database of 77 Cng isolates
Number of subjects: 183
Study 21573144 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic diversity analysis
Number of subjects: 183
Study 21573144 — intervention group
Group type: EXPERIMENTAL
Intervention: Divergence time testing
Number of subjects: 183
Study 19620518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine particles (150 microg/m(3)) plus ozone (120 parts per billion) for 2 hours with Bosentan (250 mg) pretreatment
Number of subjects: 81
Study 19620518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine particles (150 microg/m(3)) plus ozone (120 parts per billion) for 2 hours with Vitamin C (2 g) pretreatment
Number of subjects: 81
Study 19620518 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine particles (150 microg/m(3)) plus ozone (120 parts per billion) for 2 hours with placebo pretreatment
Number of subjects: 81
Study 19620518 — intervention group
Group type: EXPERIMENTAL
Intervention: Particles plus ozone, particles, ozone, and filtered air in Toronto
Number of subjects: 81
Study 19620518 — intervention group
Group type: COMPARATOR
Intervention: Filtered air in Toronto
Number of subjects: 81
Study 16842608 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfume exposure
Number of subjects: 42
Study 16842608 — intervention group
Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 42
Study 14556866 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 5035
Study 14556866 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 5035
Study 10856394 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (100 mg)
Number of subjects: 132
Study 10856394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 9200388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of nicorandil (2 mg)
Number of subjects: 20
Study 9200388 — intervention group
Group type: COMPARATOR
Intervention: Coronary revascularization only (Control)
Number of subjects: 20
Study 8268898 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose diuretic therapy
Number of subjects: 0
Study 2871219 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ketobemidon
Number of subjects: 67
Study 2871219 — intervention group
Group type: COMPARATOR
Intervention: 50 mg indomethacin
Number of subjects: 67
Study 29101645 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 593
Study 29101645 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 593
Study 27756477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 3158
Study 27756477 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 3158
Study 25239412 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic patterns in patients with isolated lymphadenopathy
Number of subjects: 0
Study 25239412 — intervention group
Group type: EXPERIMENTAL
Intervention: High numbers of IgG4-positive plasma cells
Number of subjects: 0
Study 21782923 — intervention group
Group type: EXPERIMENTAL
Intervention: WM therapy
Number of subjects: 505
Study 21782923 — intervention group
Group type: COMPARATOR
Intervention: CM therapy
Number of subjects: 505
Study 20145433 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg benidipine once daily (n = 20, group A)
Number of subjects: 40
Study 17512157 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweat patch testing
Number of subjects: 63
Study 15823831 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 166
Study 15823831 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol 2 mg/norethisterone acetate 1 mg (E2/NETA)
Number of subjects: 166
Study 15823831 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 166
Study 11916779 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 1.5 mg/kg before graft reperfusion
Number of subjects: 36
Study 11916779 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 36
Study 9861558 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diagnostic interventions
Number of subjects: 968
Study 9893773 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose formoterol Turbuhaler 6 micrograms b.i.d.
Number of subjects: 397
Study 9893773 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 0.5 mg q.i.d.
Number of subjects: 397
Study 9893773 — intervention group
Group type: COMPARATOR
Intervention: Placebo from Turbuhaler
Number of subjects: 397
Study 1679391 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA, 450 mg daily)
Number of subjects: 26
Study 1679391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 7060823 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium meclofenamate (300 mg daily)
Number of subjects: 30
Study 7060823 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (900 mg daily)
Number of subjects: 30
Study 7060823 — intervention group
Group type: COMPARATOR
Intervention: Control (Spine movement)
Number of subjects: 30
Study 30515705 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of adequately iodized salt
Number of subjects: 1263
Study 30515705 — intervention group
Group type: COMPARATOR
Intervention: Consumption of inadequately iodized salt
Number of subjects: 1263
Study 30515705 — intervention group
Group type: COMPARATOR
Intervention: Presence of goitre
Number of subjects: 1263
Study 26925992 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (SSBM) 3 times a week for 10 minutes over 4 weeks
Number of subjects: 60
Study 26925992 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 22572632 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise training (n=27)
Number of subjects: 43
Study 22572632 — intervention group
Group type: COMPARATOR
Intervention: Stretching control treatment (n=16)
Number of subjects: 43
Study 21441781 — intervention group
Group type: EXPERIMENTAL
Intervention: REVAXIS
Number of subjects: 760
Study 21441781 — intervention group
Group type: COMPARATOR
Intervention: DT Polio
Number of subjects: 760
Study 19619443 — intervention group
Group type: EXPERIMENTAL
Intervention: TP regimen (docetaxel 70 mg/m² on Day 1 and DDP 80 mg/m² on Day 2 for induction; docetaxel 60 mg/m² on Day 1 and DDP 80 mg/m² on Day 2 for concurrent chemotherapy)
Number of subjects: 57
Study 19619443 — intervention group
Group type: COMPARATOR
Intervention: DDP regimen (DDP 80 mg/m² on Day 1 for concurrent chemotherapy)
Number of subjects: 57
Study 17764783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure bag at 300 mm Hg
Number of subjects: 60
Study 17764783 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual push‐pull system
Number of subjects: 60
Study 17764783 — intervention group
Group type: COMPARATOR
Intervention: Gravity
Number of subjects: 60
Study 14980192 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 63
Study 14980192 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 63
Study 11495215 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptive users (nonsmokers)
Number of subjects: 60
Study 11495215 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum administration
Number of subjects: 60
Study 11495215 — intervention group
Group type: COMPARATOR
Intervention: OC nonusers
Number of subjects: 60
Study 9306352 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyacrylonitrile membrane (PAN)
Number of subjects: 0
Study 9306352 — intervention group
Group type: COMPARATOR
Intervention: Polysulphone (PS) membrane
Number of subjects: 0
Study 9306352 — intervention group
Group type: COMPARATOR
Intervention: Acrylonitrile copolymer (AN 69) membrane
Number of subjects: 0
Study 9306352 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan (CUP) membrane
Number of subjects: 0
Study 8216039 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 2
Number of subjects: 20
Study 8216039 — intervention group
Group type: EXPERIMENTAL
Intervention: Scotchbond 2 with dentine roughening
Number of subjects: 20
Study 8216039 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripton
Number of subjects: 20
Study 8216039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisma Universal Bond 2
Number of subjects: 20
Study 2893410 — intervention group
Group type: EXPERIMENTAL
Intervention: Suriclone (2 mg/day)
Number of subjects: 33
Study 2893410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (25 mg/day)
Number of subjects: 33
Study 29310679 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured teleconference re‐visit with study personnel and commitment contract
Number of subjects: 810
Study 29310679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 810
Study 29310679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily
Number of subjects: 810
Study 27723637 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% hyaluronan gel adjunctive to scaling and root planing
Number of subjects: 20
Study 27723637 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone (Control)
Number of subjects: 20
Study 24794469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral oximetry monitoring
Number of subjects: 40
Study 22605573 — intervention group
Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA)
Number of subjects: 6183
Study 22605573 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated fatty acids (MUFA)
Number of subjects: 6183
Study 22605573 — intervention group
Group type: COMPARATOR
Intervention: Total fat, polyunsaturated fatty acids (PUFA), and trans-fat
Number of subjects: 6183
Study 20972340 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise
Number of subjects: 33
Study 20972340 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exposure
Number of subjects: 33
Study 20972340 — intervention group
Group type: COMPARATOR
Intervention: Graded exercise and graded exposure (combined)
Number of subjects: 33
Study 18689509 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (daughter strain)
Number of subjects: 0
Study 18689509 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus reuteri ATCC 55730 (parent strain)
Number of subjects: 0
Study 15928070 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose carboplatin, etoposide and cyclophosphamide (CarboPEC) with haematopoietic stem cell support (arm B)
Number of subjects: 280
Study 15928070 — intervention group
Group type: COMPARATOR
Intervention: Conventional salvage chemotherapy (four cycles of cisplatin, ifosfamide and etoposide or vinblastine) (arm A)
Number of subjects: 280
Study 12802484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (50 mg)
Number of subjects: 12
Study 12802484 — intervention group
Group type: COMPARATOR
Intervention: Saline (20 ml)
Number of subjects: 12
Study 10595478 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 5
Study 10595478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sincalide
Number of subjects: 5
Study 10595478 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no medication)
Number of subjects: 5
Study 8712441 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ondansetron (0.1 mg/kg for children ≤ 40 kg; 4 mg for children > 40 kg)
Number of subjects: 375